Odronextamab Recommended for EU Approval by the CHMP to Treat R/R Follicular Lymphoma and DLBCL July 1, 2024
Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with R/R Follicular Lymphoma July 1, 2024
Pivotal Ph 2 Trial of Cemacabtagene Ansegedleucel (cema-cel) as 1L Treatment in Large B-Cell Lymphoma (LBCL) patients initiated June 25, 2024
Calquence + chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. SOC in patients with untreated mantle cell lymphoma in ECHO Ph 3 trial June 18, 2024
Initial Data from Investigator-Initiated Ph 2 Trial of ZYNLONTA® in Patients with R/R MZL Announced May 14, 2024
Calquence combo regimen demonstrated statistically significant and clinically meaningful PFS improvement in 1L MCL in ECHO Ph 3 trial May 7, 2024
Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with R/R EBV+ PTCL Announced April 16, 2024
Enrollment in Part 2 dose expansion initiated in LOTIS-7 Trial of ZYNLONTA® + Glofitamab or Mosunetuzumab in Patients with R/R B-cell NHL April 9, 2024
Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML published in Leukemia & Lymphoma April 8, 2024
Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy Announced April 2, 2024
Enrollment Completed for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with R/R PCNSL March 26, 2024
Lacutamab monotherapy development in PTCL to be discontinued after the anti-KIR3DL2 antibody fell short in Ph Ib trial March 26, 2024
FDA issued CRLs for the BLAs for odronextamab in R/R follicular lymphoma (FL) and in R/R DLBCL, each after two or more lines of systemic therapy March 26, 2024
FDA Accepts BLA Resubmission Of LYMPHIR™ (Denileukin Diftitox) For The Treatment Of Adults With R/R Cutaneous T-Cell Lymphoma March 26, 2024
Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy March 18, 2024
